Rem Desibiru Can we supply enough to each country? Challenge New Corona May 5 8:16
Regarding the emergency use of a drug called lemdesibir for severe coronavirus patients in the United States, it will be a challenge for scientists of WHO = World Health Organization to provide sufficient supply to each country in the future. I showed the view.
Lemdesibir is a drug under development that has been studied for the treatment of Ebola hemorrhagic fever, and the US Food and Drug Administration (FDA) approved emergency use of the new coronavirus for critically ill patients on the 1st of this month.
About this decision, WHO Chief Scientist Somiya Swaminathan said in an interview with NHK, "Will each country begin the process of urgent approval of the drug. And whether or not the drug can be supplied to countries where it may be needed. "He said that the issue will be whether the drug can be sufficiently supplied in the future.
"In a pandemic situation, it would be useless for one country or several countries to monopolize drugs or vaccines," says Swaminathan. It cannot be said that it is safe, ”he said, saying that if the development of therapeutic drugs and vaccines progresses, international coordination will be necessary, such as supplying them to countries where they are needed.
On the other hand, about the influenza drug "Abigan" developed by a Japanese pharmaceutical company, "I can get information just to judge whether it is effective for patients with new coronavirus at this stage or at what stage of disease No, we are looking forward to the results of clinical trials conducted in Japan and abroad. "
"Production targeting 1 million people in December"
According to Gilead Sciences, a major US pharmaceutical company that develops lemdecivir, there are 140,000 doses of remdesibir on the 1st of this month, assuming that the patient will be administered for 10 days. , Donating to medical institutions that treat seriously ill patients.
And, if necessary, it will produce 500,000 for October and 1 million for December.
“I don't expect dramatic effects, but could it help?”
Dominique Costa Riola, chief director of the French National Institute for Health Sciences, who is conducting a clinical trial of "lemdecivir", said in an interview with NHK, "It seems that patients with the new coronavirus have a certain therapeutic effect. In the first place, lemdecivir is a drug designed for the treatment of another disease. I don't expect dramatic effects, but it will help. "
In Inserm,
▼ In addition to “lemdecibir”,
▼ medicine combining “lopinavir” and “ritonavir” that suppresses the onset of AIDS, and
▼ clinical trials such as “hydroxychloroquine”, a type of “chloroquine” used to treat malaria. carried out have,
Kosutariora said said, "at this stage, must continue clinical trials in a number of people before issuing the only reason it is not. conclusion say what medicine is better", safety He also showed the need to carefully evaluate the effectiveness and effectiveness.